Sign In
Buy ARGX
$813.14
+10.97 (+1.37%)
At Close: Jun 03, 2026
Best Momentum Stocks to Buy for July 31st
11:16am, Wednesday, 31'st Jul 2024
ARGX, VZLA, and SBFG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 31, 2024.
New Strong Buy Stocks for July 31st
08:41am, Wednesday, 31'st Jul 2024
SBFG, APOG, ARGX, VZLA and SVM have been added to the Zacks Rank #1 (Strong Buy) List on July 31, 2024.
Argenx (ARGX) Upgraded to Buy: Here's What You Should Know
01:00pm, Tuesday, 30'th Jul 2024
Argenx (ARGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Argenx (ARGX) Stock Outpacing Its Medical Peers This Year?
10:41am, Tuesday, 30'th Jul 2024
Here is how argenex SE (ARGX) and Canopy Growth Corporation (CGC) have performed compared to their sector so far this year.
argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
01:00am, Thursday, 25'th Jul 2024
$478 million in second quarter global net product sales First CIDP patients treated with VYVGART ® Hytrulo following June 21 st FDA approval On track to begin four additional registrational studies a
argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024
01:00am, Thursday, 18'th Jul 2024
July 18, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today a
First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADA
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China's National Medical Products Administration (NMP
ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients
Argenx (ARGX) Surges 11.7%: Is This an Indication of Further Gains?
05:10am, Tuesday, 25'th Jun 2024
Argenx (ARGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Why Is European Drugmaker Argenx Stock Trading Higher On Monday?
12:43pm, Monday, 24'th Jun 2024
Friday, the FDA approved Argenx SE's ARGX Vyvgart Hytrulo for use in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder
11:20am, Monday, 24'th Jun 2024
Per argenx (ARGX), the label expansion to Vyvgart Hytrulo makes it the first FDA-approved medication with a novel mechanism of action to treat chronic inflammatory demyelinating polyneuropathy.
Argenx Surges After Its Bread-And-Butter Drug Wins Another FDA Approval
09:34am, Monday, 24'th Jun 2024
Argenx stock surged Monday after the FDA approved its drug, Vyvgart Hytrulo, for patients with an autoimmune condition known as CIDP.
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
04:50pm, Friday, 21'st Jun 2024
VYVGART® Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP)
argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients' during its Upcoming R&D Day on July 16, 2024
01:00am, Monday, 17'th Jun 2024
R&D Day presentations to include recent Phase 2 datasets in Sjogren's disease (efgartigimod) and multifocal motor neuropathy (empasiprubart) that support advancement to Phase 3 development
